App-Quantinova.ai

Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).

Bert H. O'Neil - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Differences in relapse-free survival (RFS) and survival after relapse (SAR) in right (R) versus left (L) stage I-III colon cancer (CCa).

Hagen F. Kennecke - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Population-based assessment of disease free survival (DFS) as a surrogate endpoint (SE) of 5 year overall survival (5Y OS) in stage I-III rectal (RC) and colon cancer (CC).

Richard M. Lee-Ying - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Re-evaluating the optimal threshold for lymph node (LN) harvest in colon cancer: Insights from a population-based study.

Joseph Del Paggio - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs mfolfox 6 and bevacizumab (Bev) for patients (pts) with stage II/ III rectal cancer receiving pre-operative chemoradiation.

Al Bowen Benson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

5-fluorouracil + leucovorin

Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial.

Christopher J. O'Callaghan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance)

Ghassan K. Abou-Alfa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Doxorubicin

A multicentre, open-label phase II study of irinotecan, capecitabine (Xeloda), and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Arthur Gregory Ang Lui - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Capecitabine

Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.

James C. Yao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Somatostatin

Association of disease progression, health-related quality of life (HRQoL), and utility in patients (pts) with advanced, nonfunctional, well-differentiated gastrointestinal (GI) or lung neuroendocrine tumors (NET) in the phase 3 RADIANT-4 trial.

Simron Singh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

N/A

Overall survival of patients with pancreatic adenocarcinoma and BRCA1 or BRCA2 germline mutation.

Kyaw Lwin Aung - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Overall survival in METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Bernard J. Escudier - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Nivolumab

First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).

Jose Manuel Ruiz Morales - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Pazopanib

DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny.

Gabriel G. Malouf - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).

Daniel Peter Petrylak - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cisplatin

Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).

Jonathan E. Rosenberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Enfortumab vedotin

Genome wide association study of cisplatin-induced peripheral neuropathy (CIPN) in testicular cancer survivors.

Omar El Charif - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Cisplatin

Andrea Necchi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Germ cell tumor

N/A

Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).

J. Connor Wells - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

N/A

Filters

28841 Abstracts